Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00955773
First received: August 6, 2009
Last updated: July 12, 2012
Last verified: July 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2011
  Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)